TX SR703

Suspends Senate Rule 12.03 to allow the conference committee on Senate Bill 2308 to make changes beyond the scope of disagreement between House and Senate versions

SB 2308 establishes a consortium to conduct FDA drug development clinical trials with ibogaine to seek approval for treating opioid use disorder, co-occurring substance use disorders, and other neurological or mental health conditions

Removes the original grant program structure administered by the Health and Human Services Commission and replaces it with a consortium model requiring membership of at least one drug developer, one institution of higher education, and one hospital

Requires consortiums to submit detailed proposals including clinical trial designs, FDA approval strategies, plans for breakthrough therapy designation, intellectual property arrangements, and financial disclosures verifying ability to match state funding with non-state sources

Allocates at least 20% of revenue from intellectual property and commercial rights arising from the trials to the state, with 25% of the state's share designated for Texas veterans assistance programs